Highest-materiality recent filing
Oramed extends Scilex payment obligations; receives $0.5M, $5M due July 31
Scilex owes ~$29.5M on Tranche A Note and ~$6.7M on Tranche B Note amortization as of June 30, 2026.
Lifeward acquired Oramed's wholly-owned subsidiary Oratech for 1,250,363 ordinary shares, 1,006,113 pre-funded warrants, and share purchase warrants.
Oramed deferred its right to receive an amortization payment from Scilex due Oct 1, 2025; payment was made in Nov 2025.
Oramed to receive up to 49.9% beneficial ownership in Lifeward via shares, pre-funded warrants, plus 4% revenue sharing on ReWalk net sales (max 10 years).
Oramed receives $18M payment from Scilex, approves $0.25/share dividend
$18M payment from Scilex closes Option Agreement; current returns total $118M on $99.5M investment.
Oramed reports nine-month 2025 net income of $65M, up from loss of $6.1M
Net income (pre-tax) of $65.0M vs. $6.1M loss; basic EPS $1.30, diluted $1.26.
Repurchased 1,155,367 shares from HTIT Biotech at $2.23/share for $2.58M total; shares cancelled.
Oramed grants Scilex option to repurchase Penny Warrants for up to $27M; clarifies warrant terms
Scilex pays $1.5M option fee in two installments ($750K by Aug 8, 2025; $750K by Dec 16, 2025).
Oramed invests $36.9M in Alpha Tau, acquires 14.1M shares at $2.612/share
Oramed subsidiary purchased ~14.1M shares of Alpha Tau (NASDAQ: DRTS) for $36.9M ($2.612/share) via registered direct offering.
RoyaltyVest (50% owned by Oramed) obtains exclusive license to develop, manufacture and commercialize ZTlido (lidocaine 1.8%) and SP-103 outside the U.S.
Oramed spins off oral insulin into OraTech JV with HTIT; $75M total investment, Nasdaq IPO planned
HTIT to invest $60M, Oramed $15M into OraTech; Oramed shareholders to receive direct stake in new Nasdaq-listed company.
Oramed extends Scilex note maturity to Dec 2025; receives 3.25M Scilex shares as consideration
Remaining principal on Tranche A Note is $7.675M; maturity extended from March 21, 2025 to December 31, 2025.
Oramed defers Scilex $6.25M amortization; receives 2.5M free-trading Scilex shares
Initial $6.25M amortization due Jan 2, 2025 deferred to Jan 31; further deferral to Oct 2026 conditional on royalty grant.
Oramed recieves $13.2M from Scilex, slashing Tranche A principal to $7.7M
Scilex paid ~$13.2M on Dec 13, 2024, satisfying the $15M installment due Dec 21.
Oramed restructures Scilex debt: exchanges $25M note for convertible notes, warrants, and royalty
Oramed exchanged $22.5M of its Scilex note for a $25M 5.5% convertible note due 2026 and 3.75M warrants at $1.09.
Oramed signs $11.5M CRO agreement for Phase 3 trial of ORMD-0801 in type 2 diabetes
Oramed Ltd. subsidiary retained InClin as CRO for planned Phase 3 trial of oral insulin candidate ORMD-0801.
Oramed & Scilex amend note: $2M prepayment, warrant exercise, liquidity waiver
Scilex pays Oramed $2M Sept 23: $1.7M to March 2025 amort, $300K buys back 4M $11.50 warrants.
Oramed CFO David Silberman resigns, effective July 12, 2024
David Silberman stepped down as CFO, Treasurer and Secretary for personal reasons.
HTIT completed Phase 3 for oral insulin in China, in final regulatory approval; JV definitive agreement with $70M from HTIT, $20M from Oramed.
Oramed forms JV with HTIT for oral insulin; HTIT contributes $70M, Oramed $20M + IP
Joint venture will develop oral insulin and POD technology; HTIT contributes $70M cash, Oramed $10M cash + $10M in ORMP shares.
Oramed receives $101.875M senior secured note from Scilex with warrants for 17M shares
Principal $101,875,000, 18-month maturity, interest SOFR+8.5% (4% floor), paid in kind.
Scilex declared winning bidder for its own securities from Sorrento; aggregate consideration ~$110M plus ~$12.25M legal fee assumption.
Second Amendment extends Sale Order deadline to Aug 25, 2023; reduces Scilex warrants from ~1.39M to 693K public and from ~3.1M to 1.55M private.
Oramed to acquire Scilex securities from Sorrento for $105M; provides $100M DIP loan
Oramed will purchase Scilex common and preferred stock plus warrants from Sorrento for $105M total.
Purchase price of $105M for Scilex common (59.7M shares), Series A preferred (29.1M shares), and warrants.
Oramed Phase 3 oral insulin trial fails; discontinues T2D program
Phase 3 ORA-D-013-1 of ORMD-0801 missed primary endpoint: mean A1C change at 26 weeks.
On June 6, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Avraham Gabay to serve as the Chief Financial Officer, Treasurer and Secretary of the Company, effective as of June 18, 2024.
On May 10, 2024, David Silberman, the Chief Financial Officer, Treasurer and Secretary (the “CFO”) of Oramed Pharmaceuticals Inc. (the “Company”), resigned from his positions with the Company for personal reasons, effective as of July 12, 2024.
On March 12, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Yehuda Reznick to serve as a director, effective as of April 1, 2024, to fill an existing vacancy on the board of directors (the “Board”).
On January 17, 2024, Mr. Yadin Rozov, a member of the Board of Directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”), notified the Company of his intention to resign from the Board for personal reasons, effective immediately.
On December 18, 2023, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024.
On April 27, 2023, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Mr. Benjamin Shapiro to serve as a director to fill the resulting vacancy, effective as of May 1, 2023.
On March 30, 2022, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Mr. Yadin Rozov to serve as a director to fill the resulting vacancy, effective as of April 1, 2022.
Max materiality 0.90 · Median 0.60 · Most common event other_material